These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38294085)

  • 1. The applicability of the central line-associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients.
    van den Bosch CH; Frakking FNJ; Loeffen YGT; van Tinteren H; van der Steeg AFW; Wijnen MHWA; van de Wetering MD; van der Bruggen JT
    Eur J Haematol; 2024 May; 112(5):832-839. PubMed ID: 38294085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan.
    Kato Y; Hagihara M; Kurumiya A; Takahashi T; Sakata M; Shibata Y; Kato H; Shiota A; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
    J Infect Chemother; 2018 Jan; 24(1):31-35. PubMed ID: 29066217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.
    Torres D; González ML; Loera A; Aguilera M; Relyea G; Aristizabal P; Caniza MA
    Am J Infect Control; 2016 Apr; 44(4):432-7. PubMed ID: 26775931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.
    Metzger KE; Rucker Y; Callaghan M; Churchill M; Jovanovic BD; Zembower TR; Bolon MK
    Infect Control Hosp Epidemiol; 2015 Feb; 36(2):119-24. PubMed ID: 25632993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a Best Practice Prevention Bundle on Central Line-associated Bloodstream Infection (CLABSI) Rates and Outcomes in Pediatric Hematology, Oncology, and Hematopoietic Cell Transplantation Patients in Inpatient and Ambulatory Settings.
    Ardura MI; Bibart MJ; Mayer LC; Guinipero T; Stanek J; Olshefski RS; Auletta JJ
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e64-e72. PubMed ID: 32960848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition.
    See I; Iwamoto M; Allen-Bridson K; Horan T; Magill SS; Thompson ND
    Infect Control Hosp Epidemiol; 2013 Aug; 34(8):769-76. PubMed ID: 23838215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013.
    Epstein L; See I; Edwards JR; Magill SS; Thompson ND
    Infect Control Hosp Epidemiol; 2016 Jan; 37(1):2-7. PubMed ID: 26456954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of enterococcal central line-associated bloodstream infections in patients with cancer.
    Awadh H; Chaftari AM; Khalil M; Fares J; Jiang Y; Deeba R; Ali S; Hachem R; Raad II
    BMC Infect Dis; 2021 Jul; 21(1):643. PubMed ID: 34225651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of central line bundles on the timing of catheter-associated bloodstream infections and their microbiological distribution in critically ill children.
    Devrim İ; Sandal OS; Çelebi MY; Hepduman P; Gönüllü A; Atakul G; Kara AA; Oruç Y; Gülfidan G; Bayram N; Ağın H
    Eur J Pediatr; 2023 Oct; 182(10):4625-4632. PubMed ID: 37555974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients.
    Gaur AH; Bundy DG; Werner EJ; Hord JD; Miller MR; Tang L; Lawlor JP; Billett AL;
    Infect Control Hosp Epidemiol; 2017 Jun; 38(6):690-696. PubMed ID: 28399945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central line-associated bloodstream infection in childhood malignancy: Single-center experience.
    Miliaraki M; Katzilakis N; Chranioti I; Stratigaki M; Koutsaki M; Psarrou M; Athanasopoulos E; Stiakaki E
    Pediatr Int; 2017 Jul; 59(7):769-775. PubMed ID: 28376269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies: A retrospective cohort study looking for the real source of infection.
    Puin da Silva AC; Vieira MF; Freire MP; Vaz L; Bonazzi PR; Ibrahim KY; Diz MDPE; Hoff PM; Pereira J; Rocha VG; Abdala E
    Infect Control Hosp Epidemiol; 2023 Feb; 44(2):302-304. PubMed ID: 35144717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical practical approach to the surveillance definition of central line-associated bloodstream infection in cancer patients with mucosal barrier injury.
    Chaftari AM; Jordan M; Hachem R; Al Hamal Z; Jiang Y; Yousif A; Garoge K; Deshmukh P; Raad I
    Am J Infect Control; 2016 Aug; 44(8):931-4. PubMed ID: 27112370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central Line-Associated Bloodstream Infections in Children With Hematologic and Oncologic Diseases: First Prevalence Results From a University Hospital.
    Özalp Gerçeker G; Yardımcı F; Aydınok Y
    J Pediatr Oncol Nurs; 2019; 36(5):327-336. PubMed ID: 31027430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central-line-associated bloodstream infections and central-line-associated non-CLABSI complications among pediatric oncology patients.
    Kelada AS; Foster TB; Gagliano GC; Worley S; Tang A; Arakoni VA; Foster CB
    Infect Control Hosp Epidemiol; 2023 Mar; 44(3):377-383. PubMed ID: 35475427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for central line-associated bloodstream infection in pediatric oncology patients with a totally implantable venous access port: A cohort study.
    Viana Taveira MR; Lima LS; de Araújo CC; de Mello MJ
    Pediatr Blood Cancer; 2017 Feb; 64(2):336-342. PubMed ID: 27666952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging the 48-Hour Rule-Out for Central Line-Associated Bloodstream Infections in the Pediatric Intestinal Failure Population: A Retrospective Pilot Study.
    Chang MI; Carlson SJ; Nandivada P; O'Loughlin AA; Potemkin AK; Cowan E; Mitchell PD; Gura KM; Puder M
    JPEN J Parenter Enteral Nutr; 2016 May; 40(4):567-73. PubMed ID: 25567785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of removing mucosal barrier injury laboratory-confirmed bloodstream infections from central line-associated bloodstream infection rates in the National Healthcare Safety Network, 2014.
    See I; Soe MM; Epstein L; Edwards JR; Magill SS; Thompson ND
    Am J Infect Control; 2017 Mar; 45(3):321-323. PubMed ID: 27856070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Risk of Central Line-associated Bloodstream Infections in Pediatric Hematology/Oncology Patients.
    Kristinsdottir I; Haraldsson A; Gudlaugsson O; Thors V
    Pediatr Infect Dis J; 2021 Sep; 40(9):827-831. PubMed ID: 33990520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Central Line-Associated Bloodstream Infection Rates Among Children With Immune Compromised Conditions: An 11-Year Review.
    Linder LA; Gerdy C; Jo Y; Wilson A
    J Pediatr Oncol Nurs; 2018; 35(6):382-391. PubMed ID: 29665727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.